Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bapineuzumab · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Bapineuzumab 0.5 mg/kg | EXPERIMENTAL | infusion every 13 weeks for a total of 6 infusions |
| Placebo Control | PLACEBO_COMPARATOR | infusion every 13 weeks for a total of 6 infusions. |
| Bapineuzumab 1.0 m/kg | EXPERIMENTAL | infusion every 13 weeks for a total of 6 infusions. |
| Placebo Dose | PLACEBO_COMPARATOR | infusion every 13 weeks for a total of 6 infusions. |
| 0.15 mg/kg active bapineuzumab | EXPERIMENTAL | - |
| 0.15 mg/kg placebo | PLACEBO_COMPARATOR | - |
| 0.5 mg/kg active bapineuzumab | EXPERIMENTAL | - |
| 0.5 mg/kg placebo | PLACEBO_COMPARATOR | - |
| 1.0 mg/kg active bapineuzumab | EXPERIMENTAL | - |
| 1.0 mg/kg placebo | PLACEBO_COMPARATOR | - |
| 2.0 mg/kg active bapineuzumab | EXPERIMENTAL | - |
| 2.0 mg/kg placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Bapineuzumab 0.5 mg/kg | DRUG | infusion every 13 weeks for a total of 6 infusions |
| Placebo Control | DRUG | given by infusion every 13 weeks for a total of 6 infusions. |
| Bapineuzumab 1.0 m/kg | DRUG | infusion every 13 weeks for a total of 6 infusions |
| bapineuzumab | DRUG | IV, Q13w |
| placebo | OTHER | IV Q13w |
Inclusion Criteria: * Diagnosis of probable AD * Age from 50 to less than 89 * Mini-Mental Status Exam score of 16-26 inclusive * Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiv...
Top 20 of 24 competitors
Bapineuzumab is an investigational drug being studied for the treatment of Alzheimer's disease. It has been evaluated in patients with mild to moderate Alzheimer's disease in clinical trials. As of the available data, it is not approved and remains in clinical development.
Bapineuzumab is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug has been studied in clinical trials for Alzheimer's disease.
Bapineuzumab has completed Phase 3 clinical trials for Alzheimer's disease. It is an investigational drug and has not been approved by regulatory authorities. All three clinical trials listed for bapineuzumab are completed, with no active trials ongoing.
Bapineuzumab has been studied in three completed clinical trials. NCT00112073 was a Phase 2 trial with 234 participants. NCT00574132 and NCT00575055 were Phase 3 trials with 1331 and 1121 participants, respectively, all in patients with mild to moderate Alzheimer's disease.
Yes, bapineuzumab is also known as AAB-001. The Phase 2 clinical trial NCT00112073 is titled 'AAB-001 in Patients With Mild to Moderate Alzheimer's Disease,' confirming that AAB-001 is an alternative name for bapineuzumab.